×

Biotech and Pharmaceuticals Pharmaceuticals

  • FDA to publish list of drugs with no generic competitor

    CNBC's Meg Tirrell reports on the FDA planning to create a list of drugs with no generic competitor to increase competition.

  • 21st Century Oncology, which bills itself as the world's largest operator of cancer treatment centers, filed for Chapter 11 bankruptcy.

  • The Democratic-controlled Legislature gave final approval to legislation that would put Nevada at the forefront of a national movement to rein in soaring prescription drug prices. It focuses on making public the sticker prices, profits and middlemen surrounding insulin sold in Nevada. The Nevada bill would mandate that pharmaceutical companies notify...

  • MUMBAI, May 25- India's plan to bring in a law to ensure doctors prescribe medicines only by their generic names risks proliferating the sale of substandard drugs in a country where regulation is already lax, doctors and pharmaceutical executives say. Prime Minister Narendra Modi said last month that the government was looking at such a law to improve...

  • *FDA backs 21 new drugs this year vs 22 for whole of 2016. LONDON, May 25- The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.

  • ZURICH, May 24- A person in Germany treated with Roche Holding AGs new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy in a patient...

  • TRENTON, N.J.— Johnson& Johnson has reached a $33 million settlement with 42 states, resolving allegations the health care giant sold nonprescription medicines that didn't meet federal quality requirements. The case dates to 2009, when Johnson& Johnson began dozens of voluntary recalls of popular over-the-counter medicines for children and adults,...

  • WASHINGTON, May 24- U.S. Senate Republican Leader Mitch McConnell told Reuters on Wednesday he expects bipartisan support for approval of a bill authorizing taxpayer and industry funding for the U.S. Food and Drug Administration. The bill to reauthorize the Prescription Drug User Fee Act would let the FDA continue to collect hundreds of millions of dollars...

  • Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, and Zyrtec Eye Drops, the Illinois attorney general said in a news release. "Johnson& Johnson's disregard for proper manufacturing practices of children's medications was unacceptable," Illinois Attorney General Lisa Madigan said in a statement. J&J's McNeil unit previously in 2015 pleaded guilty to...

  • Vertex CEO: Our goal is to have one medicine for all CF patients

    Jeff Leiden, Vertex Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about his company's cystic fibrosis drugs and the future for biotech and pharma under the current administration.

  • DES MOINES, Iowa— A father and son whose Iowa- based egg production company caused a massive 2010 salmonella outbreak cannot further appeal their sentences for misdemeanor food safety violations, according to the U.S. Supreme Court. The highest U.S. court declined to hear the appeals of Austin "Jack" DeCoster and his son, Peter DeCoster, without comment Monday.

  • Flexion CEO on developing an alternative to opioids

    Dr. Mike Clayman, CEO of Flexion Therapeutics, Inc., discusses the opioid epidemic in the United States and the new solution Flexion has to diminish it.

  • Amgen osteoporosis drug imperiled by safety concerns

    CNBC's Meg Tirrell reports on Amgen stocks falling today after a drug risk.

  • The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration. But the new safety data, which cropped up in an otherwise successful trial, will have to be taken into consideration, delaying any FDA decision and leaving the product's future uncertain. The news is a blow for...

  • The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration. But the new safety data, which cropped up in an otherwise successful trial, will have to be taken into consideration, delaying any FDA decision and leaving the product's future uncertain. The news is a blow for...

  • SEOUL, May 19- A unit of healthcare conglomerate Johnson& Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. Janssen's lawsuit comes about a month after Samsung, an unlisted subsidiary of contract drug maker Samsung BioLogics Co Ltd, said it got U.S....

  • Mallinckrodt shares hit a session low of $39.60 after the comments and were last down 3.5 percent. The U.S. Justice Department has been investigating Mallinckrodt along with other drug companies like Gilead, Valeant and Celgene for drug pricing practices. Earlier this year, Mallinckrodt agreed to pay $100 million to settle a lawsuit alleging that a company it...

  • SACRAMENTO, Calif.— The California Senate passed a bill Thursday that would ban drug companies from giving gifts to doctors. The Senate voted 23-13 to send the bill to the Assembly. Drug companies spend more than $1.4 billion a year on gifts to California doctors, said McGuire, a Democrat who represents a district west of Sacramento.

  • *U.S. shares rise 3.4 pct, UK stock up 1.7 pct. May 18- Successful late-stage data on Shire Plc's, long-acting preventative treatment for hereditary angioedema brings the Dublin- based drugmaker one step closer to U.S. approval, it said on Thursday. It affects about one in 50,000 people, according to the U.S. National Institutes of Health.

  • *Action targets 300 medicines India categorizes as essential. MUMBAI, May 18- India's drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval. The action targets a group of more than 300 medicines that India defines as essential, whose...